Centanafadine is an investigational non-stimulant norepinephrine-dopamine reuptake inhibitor (NDRI) currently under development for the treatment of attention deficit hyperactivity disorder (ADHD). This… Read more
Centanafadine is an investigational non-stimulant norepinephrine-dopamine reuptake inhibitor (NDRI) currently under development for the treatment of attention deficit hyperactivity disorder (ADHD). This category provides essential reference materials for this pharmaceutical agent, including the active pharmaceutical ingredient, potential degradants, and related impurities. Pharmaceutical laboratories utilize these high-quality standards to conduct rigorous analytical testing and method validation throughout the drug development lifecycle. The inclusion of stable isotope labelled compounds and specific impurities, such as nitrosated derivatives, facilitates precise impurity profiling and accurate quantification during stability studies. These reference standards are critical for supporting regulatory compliance and ensuring the consistent quality control required for clinical trial materials, enabling researchers to maintain strict analytical standards when monitoring the safety and efficacy of this therapeutic candidate.